For US healthcare professionals

Patient site Prescribing Information Important Safety Information
GRANIX logo

GRANIX® is a leukocyte growth factor indicated for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Safety Information: Contraindication: GRANIX is contraindicated in patients with a history of serious allergic reactions to filgrastim or pegfilgrastim products.

READ MORE IMPORTANT SAFETY INFORMATION
Home Cost & reimbursement Patient Savings Program

GRANIX® Patient Savings Program

Financial support for cash-paying and commercially insured patients

Up to $14,000 savings per calendar year.

Pharmacist must provide a copy of and review the GRANIX Patient Savings Program
terms and conditions with the patient prior to redeeming this offer. Contact your
Teva Representative or call 1-888-587-3263 to receive your copy.

Program Benefits

  • No patient enrollment form required
  • Covers pharmacy benefit for GRANIX
  • This offer specifically applies to the syringe without needle guard
    (please see below for specific NDC codes)

Find out more about the GRANIX Patient Savings Program or other available financial assistance.

Call 1-888-587-3263 Monday through Friday 9 AM to 8 PM ET

GRANIX offers the options of self-administration or administration by
a healthcare professional*

*For administration by patients, caregivers, and healthcare professionals. Available to specialty, retail, and mail-order pharmacies via national and regional wholesalers and distributors.


Terms and Conditions: Patients are not eligible if prescriptions are paid for in part or full by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, VA, DOD, TRICARE, or by private health benefit programs which reimburse patients for the entire cost of prescription drugs. This offer is not valid for patients who are Medicare eligible and are enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., patients who are eligible for Medicare Part D but receive a prescription drug benefit through a former employer). By redeeming this offer, patients acknowledge that they are eligible and understand and agree to comply with the terms and conditions of this offer. Void if copied, transferred, purchased, altered or traded and where prohibited and restricted by law. This is not an insurance program. Teva Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time without notice. This offer may not be used with any other discount, coupon or offer. Must be 18 years or older to participate.

Patient Implications: Patient must present their primary insurance card to the pharmacist along with their GRANIX prescription to participate in this program. Patients may opt out at any time.

Commercially Insured Patients: Patients will receive savings up to $14,000 on prescriptions of GRANIX per calendar year. Maximum reimbursement limits apply and patient out-of-pocket expenses may vary.

Cash-Paying Patients: Patients will receive savings up to $14,000 on prescriptions of GRANIX per calendar year.

Pharmacist Implications: When you use this program, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental program for this prescription. Void where prohibited by law. Pharmacists should no longer apply the program benefits when patients opt out of the program.

Pharmacy Instructions for Commercially Insured Patients: Submit this claim to Therapy First Plus. A valid Other Coverage Code (e.g., 8) is required. The patient is responsible for the first $0 and the program pays up to $14,000 in savings per calendar year. Reimbursement will be received from Therapy First Plus.

Pharmacy Instructions for Uninsured/Cash-Paying Patients: Submit this claim to Therapy First Plus. A valid Other Coverage Code (e.g., 1) is required. The program pays up to $14,000 in savings per calendar year. Reimbursement will be received from Therapy First Plus.

For questions regarding processing, please call the Help Desk at 1-800-422-5604. For questions regarding eligibility or benefits, please call 1-844-218-0443. Program managed by PSKW, LLC. on behalf of Teva Pharmaceuticals.

Indication

  • GRANIX® is a leukocyte growth factor indicated for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Safety Information

  • Contraindication: GRANIX is contraindicated in patients with a history of serious allergic reactions to filgrastim or pegfilgrastim products.
  • Splenic rupture: Splenic rupture, including fatal cases, can occur following the administration of filgrastim products. Discontinue GRANIX and evaluate for an enlarged spleen or splenic rupture in patients who report upper abdominal or shoulder pain after receiving GRANIX.
  • Acute respiratory distress syndrome (ARDS): ARDS can occur in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving GRANIX, for ARDS. Discontinue GRANIX in patients with ARDS.
  • Allergic reactions: Serious allergic reactions, including anaphylaxis, can occur in patients receiving GRANIX. Reactions can occur on initial exposure. Permanently discontinue GRANIX in patients with serious allergic reactions. Do not administer GRANIX to patients with a history of serious allergic reactions to filgrastim or pegfilgrastim.
  • Use in patients with sickle cell disease: Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving filgrastim products. Consider the potential risks and benefits prior to the administration of GRANIX in patients with sickle cell disease. Discontinue GRANIX in patients undergoing a sickle cell crisis.
  • Glomerulonephritis: Glomerulonephritis can occur in patients receiving filgrastim products. The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose reduction or discontinuation of the filgrastim product. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of GRANIX.
  • Capillary leak syndrome (CLS): CLS can occur in patients receiving filgrastim products and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
  • Potential for tumor growth stimulatory effects on malignant cells: The granulocyte colony-stimulating factor (G-CSF) receptor, through which GRANIX acts, has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.
  • Most common treatment-emergent adverse reaction: The most common treatment-emergent adverse reaction that occurred in patients treated with GRANIX at the recommended dose with an incidence of at least 1% or greater and two times more frequent than in the placebo group was bone pain.

Please see Full Prescribing Information.

Reference: 1. This information is an estimate derived from the use of information under license from the following IMS Health Information Service: IMS National Sales Perspective, GRANIX® (tbo-filgrastim) injection micrograms by non-federal hospital channel September 2016. IMS expressly reserves all rights, including rights of copying, distribution, and republication (micrograms calculated as eaches x strength).